Shire Plc (SHP) Agrees to Purchase VioPharma (VPHM) for $4.2 Billion
After beating out competitors to purchase ViroPharma for $4.2 billion, Shire Plc rose to an all time high. The London based company announced Monday that it had agreed to purchase VioPharma. VioPharma also benefitted from the announcment, rising $10 to close at nearly $50 a share.
ValueWalkShire Buys ViroPharma for $4.2 Billion to Add Orphan DrugBloombergShire Plc (SHP) agreed to buy ViroPharma Inc. (VPHM) for about $4.2 billion to gain treatments for rare diseases and ease dependence on its best-selling Vyvanse pill for atten …
VioPharma, a Pennyslvania based pharmaceutical company, specializes in the treatment of rare diseases. This acquisition strengthens Shire’s already strong portfoilo of lucrative drugs.
Shire buys ViroPharma in $4.2 billion deal LONDON (AP) — The drugmaker Shire PLC plans to strengthen its rare dis… http://t.co/sikqIh1scl